Abstracts 465 GP. The patients were observed over a period of 12 months. Lung function tests and investigations on the quality of life were carried out over three visits at intervals of six months (at the beginning, after six months and after 12 months). The quality of life was measured using the Quality of Life Asthma (FLA) questionnaires, a validated disease-specific questionnaire and the EQ-5D (Euro-Qol). In addition, the treatment costs during the study time period were documented and evaluated. RESULTS: During the study, the quality of life of the control group revealed no changes statistically, while the patients in the disease management group achieved significantly higher values than those at the beginning of the study. The improvements are related particularly to the "Physical and Psychic Attributes" of the FLA, although they can also be seen in the (less sensitive) generic EQ-5D. Thus, the average EQ-5D value of 62 increased to 72, while in the control group it dropped from 65 to 60. The study data additionally shows that considerable savings are possible with disease management for asthma, especially concerning hospital services. These savings are partly counteracted with higher costs in other areas, particularly medication. CONCLUSIONS: Disease management for asthma can lead to an improvement of the patient's quality of life and a reduction in treatment costs.
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ASTHMA KNOWLEDGE AND QUALITY OF LIFE (QOL) OF ADULT ASTHMATICS
Meszaros A 1 , Vincze G 2 , Mesko A 1 ,Orosz DM 1 1 Semmelweis University, Budapest, Hungary; 2 University of Texas at Austin, Austin, TX, USA OBJECTIVE: Good asthma knowledge and compliance with treatment are critical factors for the success of any asthma management plan. The purpose of the study was to examine the QoL with the St. George's Respiratory Questionnaire (SGRQ) and a visual analogue scale (VAS). We developed a short educational program based on the WHO-EuroPharm Forum Guidelines and assessed its effectiveness by using a short questionnaire. METHODS: We selected 32 asthmatics (mean age: 39,75; range: 14,57) with long asthma history. Patients' QoL was assessed twice, before and three month after an educational seminar. .01 ). There were no significant changes in techniques for use of inhalers. The number of patients using a peak flow meter increased from 15% to 28% and all were using it correctly and regularly. CONCLUSIONS: QoL scores did not change substantially, although a slight improvement occurred in the activity, impact, and total scores in the mild group. As these patients were regularly controlled, we expected better knowledge of general asthma and inhaler use technique. We can conclude that it is necessary to refresh asthma knowledge regularly. It is also important to regularly assess patients' self-management plans by aiming to increase their effectiveness.
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IMPACT OF ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS (AECB) IN FRANCE
Duprat-Lomon I 1 , Mortier N 1 , Blin P 2 , Chevallier E 2 , Sagnier PP 3 1 Bayer Pharma, Puteaux, France; 2 Icare, Massy, France; 3 Bayer Plc, Slough, UK OBJECTIVE: The aim of this study was to define the main characteristics of patients presenting with an AECB in general practice. METHODS: This cross-sectional study was performed by a representative sample of 120 General Practitioners (GPs), selected by random pooling from a national database. Each GP was required to recruit prospectively and consequently a maximum of eight patients aged 35 years or more with AECB defined by at least one of the Anthonisen criteria. Socio-demographics, medical history of chronic bronchitis and the current episode management were collected. The Saint-George's Respiratory Questionnaire (SGRQ) was self-administered by the patients. RESULTS: One hundred one GPs recruited 417 patients from November 2000 to April 2001. The patients were on average 65 years old, with 67% over 60 years. Twenty nine percent (121) of patients were smokers and 163 (40%) were former smokers. They had been suffering from chronic bronchitis for an average of 13 years. During the last 12 months, 351 patients (85%) experienced four or less episodes of AECB (mean ϭ 3 episodes), and 52 patients (12%) were hospitalized due to the disease. FEV1 was available for 186 patients. The value was greater than 80% for 14% of the patients, between 35% and 80% for 76%, and less than 35% for 10%. Most of the patients were classified as Anthonisen 1 (289 patients, 69%), and 104 patients (25%) as Anthonisen 2. The total mean score from the SGRQ was 54 (n ϭ 275) (symptoms 62, activity 63, impact 46) and consistently increased with age, duration of chronic bronchitis, FEV1, number of AECB episodes and Anthonisen severity. CONCLUSION: This observational study confirmed the importance of risk factors and the severity of AECB in patients managed by GPs, with significant burden of disease.
